ArticleNPJ breast cancer2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Abstract read
In one paragraph
Article in NPJ breast cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis.Breast cancer research and treatment · 2024Pooled it
- Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.Breast (Edinburgh, Scotland) · 2026Observational
- Impact of HER2-Low Expression on Clinical Outcomes in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Journal of clinical medicine · 2026Article
- HER2-low status in breast cancer: clinicopathological factors and prognostic value.Archives of medical science : AMS · 2026Article
- First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam.Frontiers in oncology · 2026Article
- Interplay Between MicroRNAs and Breast Cancer Therapies: Personalized Therapeutic Potential for HER2-Low Breast Cancer.Cancers · 2025Review
- Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes.The oncologist · 2025Article
- Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis.Archives of gynecology and obstetrics · 2025Article
- Clinical Outcomes of HER2-Low Versus HER2-Zero in HR-Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.International journal of breast cancer · 2025Article
- Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups.The breast journal · 2025Article
- Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy.Drugs in context · 2025Article
- Time to focus again on matrix metalloproteinases? Results of complex network analysis involving the pathophysiology of HER2-positive breast cancer.Ecancermedicalscience · 2025Article
- Survival outcomes for HER2-low breast cancer: Danish national data.Acta oncologica (Stockholm, Sweden) · 2024Article
- The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.BMC cancer · 2024Article
- Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study.International journal of clinical oncology · 2024Article
- HER2-Low Breast Cancer: Now and in the Future.Cancer research and treatment · 2024Review
- The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.Breast cancer research and treatment · 2024Article
- Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.Thoracic cancer · 2024Article
- Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer.Breast cancer research and treatment · 2024Article
- Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Emma Zattarin *Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Daniele Presti *Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Luigi MarianiUnit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0001-6208-4084
Caterina SposettiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0003-3211-8516
Rita LeporatiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0001-6671-9809
Alice MenichettiOncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Chiara CortiDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-0359-0267
Chiara BenvenutiIRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Giovanni FucàDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0002-1560-2253
Riccardo LobefaroDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Francesca LigorioDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Leonardo ProvenzanoDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Andrea VingianiPathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Marta Del VecchioDivision of Pharmacy, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
Gaia GriguoloOncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.ORCID http://orcid.org/0000-0002-8782-4509
Marianna SiricoDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014, Meldola, Italy.
Ottavia BernocchiFarmacia Ospedaliera ASST Cremona, Viale Concordia 1, Cremona, Italy.
Antonio MarraDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0002-7310-7824
Paola ZagamiDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Elisa AgostinettoIRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.ORCID http://orcid.org/0000-0003-0295-7511
Flavia JacobsIRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Pierluigi Di MauroMedical Oncology Unit, ASST Spedali Civili, Brescia, Italy.ORCID http://orcid.org/0000-0002-1975-0923
Andrea EspositoMedical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
Carlo Alberto GiorgiOncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.ORCID http://orcid.org/0000-0001-5406-0357
Luca LalliUnit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Laura BoldriniDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Pier Paolo Berton GiacchettiDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0001-5559-7279
Ambra Carnevale SchiancaDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Valentina GuarneriOncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.ORCID http://orcid.org/0000-0002-2375-8397
Rebecca PedersiniMedical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
Agnese LosurdoIRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Alberto ZambelliIRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
Daniele GeneraliBreast Cancer Unit & Translational Research Unit, ASST Cremona, Cremona, Italy.
Carmen CriscitielloDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Giuseppe CuriglianoDivision of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-1781-2518
Giancarlo PruneriPathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID http://orcid.org/0000-0002-7963-7172
Filippo de BraudDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Maria Vittoria DieciOncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Claudio VernieriDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. claudio.vernieri@istitutotumori.mi.it.ORCID http://orcid.org/0000-0003-1577-8176
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.